Stressgen Biotechnologies Corp

SSB-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about SSB-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
July 26, 2005
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.
Show full opinionHide full opinion
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.
DON'T BUY
DON'T BUY
November 12, 2004
Trying to raise $50 million which is equivalent/more than their entire market cap.
Show full opinionHide full opinion
Trying to raise $50 million which is equivalent/more than their entire market cap.
PAST TOP PICK
PAST TOP PICK
November 9, 2004
(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
Show full opinionHide full opinion
(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
TOP PICK
TOP PICK
June 15, 2004
Holds this stock personally. Risky could double.
Show full opinionHide full opinion
Holds this stock personally. Risky could double.
VAGUE
VAGUE
December 5, 2003
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
Show full opinionHide full opinion
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
DON'T BUY
DON'T BUY
December 4, 2003
Have restructured and will need more money.
Show full opinionHide full opinion
Have restructured and will need more money.
BUY
BUY
October 7, 2003
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
Show full opinionHide full opinion
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
DON'T BUY
DON'T BUY
June 30, 2003
On their watch list. Lost a lot of maney last year.
Show full opinionHide full opinion
On their watch list. Lost a lot of maney last year.
BUY WEAKNESS
BUY WEAKNESS
May 14, 2003
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
Show full opinionHide full opinion
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
BUY
BUY
May 12, 2003
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
Show full opinionHide full opinion
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
BUY
BUY
October 2, 2002
Outlook is quite good and the price is at a good level.
Show full opinionHide full opinion
Outlook is quite good and the price is at a good level.
BUY
BUY
August 26, 2002
At a good level. Has mad a good agreement with a large pharmaceutical.
Show full opinionHide full opinion
At a good level. Has mad a good agreement with a large pharmaceutical.
WEAK BUY
WEAK BUY
May 17, 2002
In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
Show full opinionHide full opinion
In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
WEAK BUY
WEAK BUY
May 2, 2002
Well along on the approval line. Product seems to be good. The sector is suffering. A higher risk.
Show full opinionHide full opinion
Well along on the approval line. Product seems to be good. The sector is suffering. A higher risk.
WAIT
WAIT
January 15, 2002
Fairly risky, but a good risk/reward ratio. In phase 3 trials. Could double if they get into a good partnership.
Show full opinionHide full opinion
Fairly risky, but a good risk/reward ratio. In phase 3 trials. Could double if they get into a good partnership.
Showing 1 to 15 of 23 entries

Stressgen Biotechnologies Corp(SSB-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Stressgen Biotechnologies Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stressgen Biotechnologies Corp(SSB-T) Frequently Asked Questions

What is Stressgen Biotechnologies Corp stock symbol?

Stressgen Biotechnologies Corp is a OTC stock, trading under the symbol SSB-T on the (). It is usually referred to as or SSB-T

Is Stressgen Biotechnologies Corp a buy or a sell?

In the last year, there was no coverage of Stressgen Biotechnologies Corp published on Stockchase.

Is Stressgen Biotechnologies Corp a good investment or a top pick?

Stressgen Biotechnologies Corp was recommended as a Top Pick by Peter Hodson on 2005-07-26. Read the latest stock experts ratings for Stressgen Biotechnologies Corp.

Why is Stressgen Biotechnologies Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stressgen Biotechnologies Corp worth watching?

In the last year 0 stock analyst on Stockchase covered Stressgen Biotechnologies Corp. The stock is worth watching.

What is Stressgen Biotechnologies Corp stock price?

On , Stressgen Biotechnologies Corp (SSB-T) stock closed at a price of $.